For over a year, thousands of lawsuits have been working their way through a special federal court for victims who suffered bleeding while taking the atrila fibrillation drug Pradaxa.
Last year, drug maker Merck made an estimated $664 million from their popular contraceptive NuvaRing. However, pressure is mounting as studies show the devices may cause blood clots and more and more women are filing injury lawsuits.
The antipsychotic drug Risperdal has been on the market since 1994, but has made headlines in the past few months after troubling news of false marketing charges, side effect lawsuits and claims of safety data cover-ups by manufacturer Johnson & Johnson.
The popular birth control drugs Yaz and Yasmin have been tied to increased risks of blood clots, and dangerous conditions like stroke, DVT and pulmonary embolism.
DrugRisk continues to follow developments with the popular blood thinner Pradaxa, and recent news suggests bleeding risks of the drug could be driving new studies from the FDA and increased legal action against the manufacturer, Boehringer Ingelheim.
The popular once-a-month birth control device NuvaRing has been in the news lately due to pressure from generic competition and thousands of patients suffering injury or death from blood clots.
After facing federal criminal charges last year over the marketing of its antipsychotic drug Risperdal, pharma giant Johnson & Johnson now must deal with mounting lawsuits from patients who developed abnormal breast growth while using the medication.
Although Yaz and Yasmin rank among the most popular birth control pills in the world, recent studies show that the progestin hormone drospirenone used in both meds can greatly increase patients’ risks of blood clots.
DrugRisk has learned that the FDA is planning a new, widespread review of data from patients taking Pradaxa to determine if the popular blood thinning medication has greater risks for internal bleeding or blood clots than standby warfarin.
Last month Bloomberg published an article detailing Merck’s all-out legal assault on generic drug maker Actavis over the threat of generic competition for its birth control blockbuster NuvaRing.